Home > Insider Trading > Filing (0000947871-16-001204)

Filing Details

Accession Number:: 0000947871-16-001204
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-05-20 16:27:00
Reporting Period:: 2016-05-18

Filing Date:: 2016-05-20
Accepted Time:: 2016-05-20 16:27:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1626971	Corvus Pharmaceuticals Inc.	CRVS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Corvus Pharmaceuticals, Inc. 863 Mitten Road, Suite 102 Burlingame CA 94010		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2016-05-18	4,200	$11.55	5,262,650	No	4	P	Indirect	See Footnotes
Common Stock, $0.0001 Par Value	Acquisiton	2016-05-19	2,539	$12.11	5,265,189	No	4	P	Indirect	See Footnotes
Common Stock, $0.0001 Par Value	Acquisiton	2016-05-19	61	$12.75	5,265,250	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $11.17 to $11.83 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $11.52 to $12.30 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person is an employee of Advisors.
Each of the Reporting Person, GP V, Advisors, and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.